Tempest Therapeutics, Inc. — Form S-1
Filed August 21, 2026 · analyzed by the Registration Agent
S-1
— Neutral
significance 68/100
What the filing says
On August 13, 2026, Tempest entered into a purchase agreement with Lincoln Park Capital Fund, LLC for an equity line of credit of up to $50 million ($25M initial + $25M additional). Tempest issued 560,356 commitment shares to Lincoln Park immediately at no cash cost; may issue 350,223 additional commitment shares after the initial $25M is drawn. Over 24 months, Tempest may direct Lincoln Park to purchase up to 8,000,000 shares at market prices (97% of VWAP/low), with share count capped at 19.99% of pre-deal outstanding shares (3,195,881 shares) unless stockholder approval obtained or avg sale price ≥$1.39/share.
Why this rating
Significant financing; $50M max = 166% of current $30.1M market cap. Heavy dilution risk (up to 33% if all shares issued). Near-term stock likely pressured by dilution; longer-term depends on capital deployment success and clinical progress.
Extracted items
See more from August 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.